Mcl-1, Bcl-XL and Stat3 expression are associated with progression of melanoma whereas Bcl-2, AP-2 and MITF levels decrease during progression of melanoma
Open accessThe DOI matches its Crossref record; 57 of the 58 references it cites were found in a registry or an index.
Abstract
Members of the Bcl-2 family of antiapoptotic proteins (Bcl-2, Bcl-XL and Mcl-1) are key regulators of apoptosis. The purpose of the present study was to examine and better define the role of Bcl-2, Bcl-XL and Mcl-1 in the progression of melanoma. Immunohistochemical staining for Bcl-2, Bcl-XL and Mcl-1 was performed on paraffin sections of 100 cases of benign nevi, primary melanoma and metastatic melanoma. Expression was correlated with histopathologic features, clinical progress and expression of transcription factors (AP-2, MITF and p-Stat3). Bcl-2 was expressed in 100% of benign nevi and thin melanoma (<or=1.0 mm) but was less in thick melanoma (>1.0 mm) (88%), subcutaneous (62%) and lymph node metastases (35%). In contrast, Bcl-XL and Mcl-1 were expressed at lower levels in nevi and thin melanoma compared to Bcl-2 but their expression was much higher in thick melanoma and in subcutaneous and lymph node metastases (P<0.0001). Bcl-2 expression was negatively associated with tumor thickness (P<0.05) but Bcl-XL expression increased with increasing tumor thickness (P<0.05) and dermal tumor mitotic rate (P<0.05). Similarly Mcl-1 expression increased with increasing tumor thickness (P<0.09) and dermal tumor mitotic rate (P<0.17). Bcl-2 expression was positively correlated with expression of the transcription factors microphthalmia transcription factor (MITF) and nuclear AP-2 whereas Bcl-XL (and Mcl-1) expression were positively correlated with p-Stat3. This study is the first to show a clear dissociation between changes in Bcl-2 expression (downregulation) and Bcl-XL, Mcl-1 expression (upregulation) during progression of melanoma. The results were also consistent with a role for AP-2 and MITF in regulation of Bcl-2 and pStat3 in regulation of Bcl-XL. These findings have important implications for the development of treatments targeting antiapoptotic proteins in patients with melanoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Constitutive STAT3 activation leads to evasion of apoptosis and a subsequent increase in cell survival.”
From Critical analysis of the potential for targeting STAT3 in human malignancy (2013) · cites this paper as [77]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“STAT3-mediated upregulation of Bcl-xL, Bcl-2, and Mcl-1 contributes to apoptosis evasion in several cancers.77–79”
From Critical analysis of the potential for targeting STAT3 in human malignancy (2013) · cites this paper as [77]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“STAT3 transcriptionally regulates several Bcl-2 family members, including the antiapoptotic proteins Bcl-xL, Bcl-2, and Mcl-1.77”
From Critical analysis of the potential for targeting STAT3 in human malignancy (2013) · cites this paper as [77]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Expression of MITF, which correlates with increased lysosomal gene expression in melanoma cells100, decreases with disease progression97,101.”
From Mechanisms and prevention of UV‐induced melanoma (2018) · cites this paper as [97]
In the citing paper
“Furthermore, BH3-family proteins Bcl-XL and MCL-1, which disrupt the activation of autophagy by Beclin1, are upregulated in metastatic melanomas97.”
From Mechanisms and prevention of UV‐induced melanoma (2018) · cites this paper as [97]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Bcl2 family: regulators of the cellular life-or-death switch
Cory, S., & Adams, J. M. (2002) · Nature Reviews Cancer · doi:10.1038/nrc883 · Cited by 4,032 · cited 1×
“Members of the Bcl-2 (B-cell lymphoma 2) family of proteins are key regulators of apoptosis”
BackgroundProapoptotic BAX and BAK: A Requisite Gateway to Mitochondrial Dysfunction and Death
Wei, M. C., Zong, W.-X., Cheng, E. H.-Y., Lindsten, T., Panoutsakopoulou, V., Ross, A. J., Roth, K. A., MacGregor, G. R., Thompson, C. B., & Korsmeyer, S. J. (2001) · Science · doi:10.1126/science.1059108 · Cited by 3,988
bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death
Boise, L. H., González-García, M., Postema, C. E., Ding, L., Lindsten, T., Turka, L. A., Mao, X., Nuñez, G., & Thompson, C. B. (1993) · Cell · doi:10.1016/0092-8674(93)90508-n · Cited by 3,087 · cited 1×
“The protein product of the longer Bcl-X mRNA (Bcl-XL) becomes as a repressor of apoptosis”
BackgroundChen, L., Willis, S. N., Wei, A., Smith, B. J., Fletcher, J. I., Hinds, M. G., Colman, P. M., Day, C. L., Adams, J. M., & Huang, D. C. S. (2005) · Molecular Cell · doi:10.1016/j.molcel.2004.12.030 · Cited by 1,816
Involvement of the bcl -2 Gene in Human Follicular Lymphoma
Tsujimoto, Y., Cossman, J., Jaffe, E., & Croce, C. M. (1985) · Science · doi:10.1126/science.3874430 · Cited by 1,786
Cheng, E. H.-Y. A., Wei, M. C., Weiler, S., Flavell, R. A., Mak, T. W., Lindsten, T., & Korsmeyer, S. J. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00320-3 · Cited by 1,707 · cited 1×
“Bcl-2 associated X protein (Bax) and Bak are additional proapoptotic proteins that appear to be essential for induction of apoptosis”
BackgroundLetai, A., Bassik, M. C., Walensky, L. D., Sorcinelli, M. D., Weiler, S., & Korsmeyer, S. J. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00127-7 · Cited by 1,677 · cited 1×
“3 The precise interactions between the Bcl-2 proteins leading to apoptosis remain uncertain but two BH3 proteins, Bid and Bim, appear to directly activate Bax and Bak and bind to mitochondria”
BackgroundWillis, S. N., Chen, L., Dewson, G., Wei, A., Naik, E., Fletcher, J. I., Adams, J. M., & Huang, D. C. S. (2005) · Genes & Development · doi:10.1101/gad.1304105 · Cited by 1,233 · cited 1×
“Recent studies have also suggested that there may be some selectivity of the proapoptotic BH3 only proteins for particular antiapoptotic proteins for example Noxa appears to bind to Mcl-1 and Bcl-XL but not Bcl-2”
BackgroundMCL1, a gene expressed in programmed myeloid cell differentiation, has sequence similarity to BCL2.
Kozopas, K. M., Yang, T., Buchan, H. L., Zhou, P., & Craig, R. W. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.8.3516 · Cited by 961 · cited 1×
“7 Mcl-1 was first reported in differentiating myeloid cells”
BackgroundZhong, Q., Gao, W., Du, F., & Wang, X. (2005) · Cell · doi:10.1016/j.cell.2005.06.009 · Cited by 842 · cited 1×
“49 perhaps by the specific Mcl-1 ubiquitin ligase E3 (Mule)”
Background
Cited by
Items 101–200 of 201
Overcoming Resistance to Therapies Targeting the MAPK Pathway in BRAF-Mutated Tumours
Paton, E. L., Turner, J. A., & Schlaepfer, I. R. (2020) · Journal of Oncology · doi:10.1155/2020/1079827 · Cited by 32
“In tumours with acquired resistance to BRAFi therapy, STAT3 activation is associated with a poor prognosis [104, 105].”
BackgroundTherapeutic targeting of anoikis resistance in cutaneous melanoma metastasis
Neuendorf, H. M., Simmons, J. L., & Boyle, G. M. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1183328 · Cited by 29
“Studies demonstrate that STAT3 drives melanoma cell survival through the upregulation of anti-apoptotic proteins Bcl-XL, Mcl1, Cyclin D1 and survivin, and downregulation of p53 (Zhuang et al., 2007).”
BackgroundBardi, G. T., Al-Rayan, N., Richie, J., Yaddanapudi, K., & Hood, J. L. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20051235 · Cited by 27
“Increased expression of the anti-apoptotic protein BCL-XL is positively correlated to melanoma progression and phosphorylated STAT-3 (pSTAT-3) [32].”
BackgroundCritical analysis of the potential for targeting STAT3 in human malignancy
Grandis, J., & Peyser (2013) · OncoTargets and Therapy · doi:10.2147/ott.s47903 · Cited by 24
“STAT3 transcriptionally regulates several Bcl-2 family members, including the antiapoptotic proteins Bcl-xL, Bcl-2, and Mcl-1.”
Serini, S., Zinzi, A., Vasconcelos, R. O., Fasano, E., Riillo, M. G., Celleno, L., Trombino, S., Cassano, R., & Calviello, G. (2016) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2016.06.010 · Cited by 26
Jaime‐Sánchez, P., Catalán, E., Uranga-Murillo, I., Aguiló, N., Santiago, L., Lanuza, P. M., de Miguel, D., Arias, M. A., & Pardo, J. (2018) · Cell Death and Differentiation · doi:10.1038/s41418-018-0112-9 · Cited by 25
Kian, M. M., Salemi, M., Bahadoran, M., Haghi, A., Dashti, N., Mohammadi, S., Rostami, S., Chahardouli, B., Babakhani, D., & Nikbakht, M. (2020) · Drug Design Development and Therapy · doi:10.2147/dddt.s228610 · Cited by 23
“Curcumin-induced apoptosis was associated Drug Design, Development and Therapy 2020:14 submit your manuscript | www.dovepress.com DovePress 189 submit your manuscript | www.dovepress.com DovePress Drug Design, Development and Therapy 2020:14190 Drug Design, Development and Therapy 2020:14 submit your manuscript | www.…”
BackgroundTargeting inhibitor of apoptosis proteins in combination with dacarbazine or TRAIL in melanoma cells
Engesæter, B. Ø., Sathermugathevan, M., Hellenes, T., Engebråten, O., Holm, R., Flørenes, V. A., & Mælandsmo, G. M. (2011) · Cancer Biology & Therapy · doi:10.4161/cbt.12.1.15714 · Cited by 22
“, Bad, Bim, Puma and Noxa),(5-7) or inactivated, as p53,(8) while anti-apoptotic proteins, such as Mcl-1 and Bcl-X L , are reported to be overexpressed.(9) Furthermore, proteins belonging to the inhibitor of apoptosis protein (IAP) family, like XIAP,(10) survivin(11) and livin(12) have been reported to be overexpresse…”
BackgroundTseng, H., Dreyer, J., Emran, A. A., Gunatilake, D., Pirozyan, M. R., Cullinane, C. M., Dutton‐Regester, K., Rizos, H., Hayward, N. K., McArthur, G. A., et al. (2020) · International Journal of Cancer · doi:10.1002/ijc.33000 · Cited by 21
“Previous immunohistochemical (IHC) studies showed that melanoma progression was associated with an increase in levels of MCL1 and BCLXL proteins and a reduction in levels of BCL2.(13) MCL1 is also critical for survival of melanoma cells undergoing endoplasmic reticulum stress(14) and confers drug resistance.”
BackgroundSelf-citationMyeloid leukemia-1 expression in benign and malignant melanocytic lesions
Wong, R. P. C., Khosravi, S., Martinka, M., & Li, G. (2008) · Oncology Reports · doi:10.3892/or.19.4.933 · Cited by 22
Tawfik, N. M., Teiama, M. S. A., Iskandar, S. S., Osman, A., & Hammad, S. (2023) · International Journal of Nanomedicine · doi:10.2147/ijn.s385166 · Cited by 21
Singh, S., Davis, R. K., Alamanda, V. K., Pireddu, R., Pernazza, D., Sebti, S. M., Lawrence, N. J., & Chellappan, S. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0442 · Cited by 22
Govindarajah, V., Murugan, R. S., & Nagini, S. (2010) · The Breast · doi:10.1016/j.breast.2010.08.002 · Cited by 20
Perciavalle, R. M. (2012) · doi:10.21007/etd.cghs.2012.0242 · Cited by 18
“In addition, MCL-1 is upregulated in a variety of solid tumors including hepatocellular carcinoma, pancreatic cancer, testicular cancer, cervical cancer, lung cancer, and melanoma (Chung et al., 2002; Sano et al., 2005; Sieghart et al., 2006; Song et al., 2005; Zhuang et al., 2007).”
BackgroundHartman, M. L., Rogut, M., Mielczarek-Lewandowska, A., Woźniak, M., & Czyż, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21113749 · Cited by 19
“It has also been demonstrated that the BCL-X L level was positively correlated with the level of active STAT3 in melanoma [79].”
The BH3-only protein BimL overrides Bcl-2-mediated apoptosis resistance in melanoma cells
Plötz, M., Gillissen, B. F., Quast, S.-A., Berger, A., Daniel, P. T., & Eberle, J. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.02.005 · Cited by 17
Tagami-Nagata, N., Serada, S., Fujimoto, M., Tanemura, A., Nakatsuka, R., Ohkawara, T., Murota, H., Kishimoto, T., Katayama, I., & Naka, T. (2015) · Experimental Dermatology · doi:10.1111/exd.12802 · Cited by 15
Liggi, S., Drakakis, G., Hendry, A. E., Hanson, K., Brewerton, S. C., Wheeler, G. N., Bodkin, M. J., Evans, D. A. P., & Bender, A. (2013) · Molecular Informatics · doi:10.1002/minf.201300102 · Cited by 20
Immunohistochemical profile of oral mucosal and head and neck cutaneous melanoma
Alaeddini, M., & Etemad‐Moghadam, S. (2014) · Journal of Oral Pathology and Medicine · doi:10.1111/jop.12235 · Cited by 17
Zhao, R., Fan, S., Han, J., & Liu, G. (2014) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2014.929028 · Cited by 15
“Furthermore, Mcl-1 differs from other members of the Bcl-2 family in different tissue distribution and has a shorter half-life (Krajewshi et al., 1995; Zhuang et al., 2007).”
BackgroundDrukker, L., Margulis, A. R., Chaouat, M., Levitzki, R., Maiorenko, E., & Bassat, H. B. (2013) · Journal of Receptors and Signal Transduction · doi:10.3109/10799893.2013.838785 · Cited by 15
Engesæter, B. Ø., Engebraaten, O., Flørenes, V. A., & Mælandsmo, G. M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0045492 · Cited by 16
“Inhibitor of Apoptosis Proteins (IAPs) are reported to be overexpressed [10,11,12,13].”
Niessner, H., Kosnopfel, C., Sinnberg, T. W., Beck, D., Krieg, K., Wanke, I., Lasithiotakis, K. G., von Bonin, M., Garbe, C., & Meier, F. E. (2017) · Experimental Dermatology · doi:10.1111/exd.13372 · Cited by 15
Manganoni, A. M., Rossi, M., Sala, R., Venturini, M., Sereni, E., Ungari, M., Marocolo, D., Lonardi, S., & Calzavara‐Pinton, P. (2011) · Experimental Dermatology · doi:10.1111/j.1600-0625.2011.01397.x · Cited by 16
Rudner, J., Elsässer, S. J., Jendrossek, V., & Huber, S. M. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.09.002 · Cited by 14
BH 3‐only proteins – possible proapoptotic triggers for melanoma therapy
Plötz, M., & Eberle, J. (2014) · Experimental Dermatology · doi:10.1111/exd.12399 · Cited by 16
Or, C.-H. R., Su, H.-L., Lee, W.-C., Yang, S.-Y., Ho, C., & Chang, C. (2016) · Oncology Reports · doi:10.3892/or.2016.5201 · Cited by 15
Cell cycle regulatory markers in melanoma: New strategies in diagnosis and treatment.
Afrang, N., & Honardoost, M. (2019) · Europe PMC (PubMed Central) · doi:10.34171/mjiri.33.96 · Cited by 13
“Scientists have suggested that STAT3 mRNA prevention may lead to reduction in VEGF protein level and eventually melanoma molecular therapy (23).”
BackgroundDrug Targeting of Oncogenic Pathways in Melanoma
Fecher, L. A., Amaravadi, R. K., Schuchter, L. M., & Flaherty, K. T. (2009) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2009.03.004 · Cited by 14
Isatin inhibits the proliferation and invasion of SH-SY5Y neuroblastoma cells
Xu, P., Hou, L., Ju, C., Zhang, Z., Sun, W., Zhang, L., Song, J., Lv, Y., Liu, L., CHEN, Z., et al. (2016) · Molecular Medicine Reports · doi:10.3892/mmr.2016.4850 · Cited by 14
Kim, M.-J., Kwon, S.-B., Ham, S. H., Jeong, E.-S., Choi, Y., Choi, K. D., Hong, J. T., Jung, S. H., & Yoon, D. (2015) · Journal of Microbiology and Biotechnology · doi:10.4014/jmb.1501.01050 · Cited by 13
miR-337 can be a key negative regulator in melanoma
Xiao, W., Yao, E., Zheng, W., Tian, F., & Tian, L. (2017) · Cancer Biology & Therapy · doi:10.1080/15384047.2017.1323581 · Cited by 13
“At present, the incidence of melanoma is increasing at an annual rate of 3–5%, its fatality rate is about 79%, and it has obvious family heredity.(1-4) Taking advantage of contemporary technologies to identify molecular alterations in melanoma, are therefore urgently required to facilitate the development of strategie…”
BackgroundZheng, L., Wong, Y., Shao, M., Huang, S., Wang, F., & Chen, J. (2018) · Molecular Medicine Reports · doi:10.3892/mmr.2018.9035 · Cited by 12
“The expression of Mcl-1 is also known to increase in melanoma with disease progression (21).”
Morales, A., Álvarez, A., Arvelo, F. A., Suarez, A. I., Compagnone, R. S., & Galindo‐Castro, I. (2011) · APOPTOSIS · doi:10.1007/s10495-011-0638-5 · Cited by 14
Khomenko, T., Deng, X., Ahluwalia, A., Tarnawski, A. S., Patel, K. N., Sandor, Z., & Szabó, S. (2014) · Digestive Diseases and Sciences · doi:10.1007/s10620-013-2807-6 · Cited by 11
“STAT3 activation correlates with the expression of Bcl-xL and Mcl-1, consistent with the induction of anti-apoptotic genes, which promote the survival and cell progression [22].”
BackgroundPotential of natural source polysaccharides for the treatment of anemia: A review
Hou, H., Wu, Q., Yang, L., Sun, Y., Bai, N., & Chen, H. (2026) · Industrial Crops and Products · doi:10.1016/j.indcrop.2026.123211 · Cited by 9
Cancer stem cells in cutaneous melanoma
Wouters, J., Vankelecom, H. E. J., & van den Oord, J. (2009) · Expert Review of Dermatology · doi:10.1586/edm.09.17 · Cited by 11
Kuo, M., Dai, W., Chang, J., Chang, J., Lee, T., & Chang, C. (2024) · Environmental Toxicology · doi:10.1002/tox.24193 · Cited by 9
“47 Moreover, BCL-xL is pivotal to sustaining melanoma cell survival, as evidenced by its ability to drive chemoresistance when overexpressed while facilitating drug sensitization when downregulated by genetic or pharmacological approaches.”
BackgroundMachiraju, D., Moll, I., Gebhardt, C., Sucker, A., Buder‐Bakhaya, K., Schadendorf, D., & Hassel, J. C. (2018) · Melanoma Research · doi:10.1097/cmr.0000000000000435 · Cited by 10
Computational Analysis of Drug Resistance Network in Lung Adenocarcinoma
Kara, A., Özgür, A., Tekin, Ş., & Tutar, Y. (2021) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520621666210218175439 · Cited by 10
Kempkensteffen, C., Hinz, S., Johannsen, M., Krause, H., Magheli, A., Christoph, F., llermann, J. K. O., Schrader, M. G., Schostak, M., Miller, K., et al. (2009) · Tumor Biology · doi:10.1159/000215826 · Cited by 9
“and has been shown to be over-expressed in many solid human tumours [”
BackgroundSeehase, M., Houthuizen, P., Jellema, R. K., Collins, J. J. P., Bekers, O., Breuer, J., & Kramer, B. W. W. (2013) · Pediatric Research · doi:10.1038/pr.2013.10 · Cited by 9
“The following dilutions were used for antibodies: 1:1,000 for monoclonal anti-β-actin clone AC-1 (Sigma-Aldrich), anticleaved-caspase-3 (Asp175) (Cell Signaling Technology, Danvers, MA) (30), anticleavedcaspase-9 (Novus Biologicals, Littleton, CO), anti-Bcl-xL (Cell Signaling Technology), anti-phospho-AKT (Cell Signal…”
BackgroundInfluentialKim, K., Hwangbo, S., Kim, H., Kim, Y. B., No, J. H., Suh, D. H., & Park, T. (2022) · Journal of Gynecologic Oncology · doi:10.3802/jgo.2022.33.e27 · Cited by 8
“In accordance with a previous study [11], intensity of staining was judged on an arbitrary scale of 0 to 4: no staining (0), weakly positive staining (1), moderately positive staining (2), strongly positive staining (3), and very strongly positive staining (4).”
MethodAntiangiogenic and antiapoptotic treatment in advanced melanoma
Nikolaou, V. A., Stratigos, A., Bafaloukos, D. I., & Katsambas, A. (2013) · Clinics in Dermatology · doi:10.1016/j.clindermatol.2012.08.018 · Cited by 8
Dissecting the In Vivo Leukemogenic Potency of Bclxl
Scherzer, K. S. M. T. (2014) · Journal of Leukemia · doi:10.4172/2329-6917.1000158 · Cited by 7
“Increased level of BCLxl results in decreased overall patient survival and is a marker for tumor progression [2,15-18].”
BackgroundMadrid, A., Avola, R., Graziano, A. C. E., Cardile, V., & Russo, A. (2025) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2025.120162 · Cited by 6
Towards a quantitative understanding of the MITF-PIAS3-STAT3 connection
Thingnes, J., Lavelle, T. J., Gjuvsland, A. B., Omholt, S. W., & Hovig, E. J. (2012) · BMC Systems Biology · doi:10.1186/1752-0509-6-11 · Cited by 7
“STAT3 has been implicated in neoplastic progression with an increased contribution especially in metastatic melanoma [42].”
BackgroundNaffouje, S. A., Naffouje, R., Chen, J., & Salti, G. I. (2016) · Anticancer Research · doi:10.21873/anticanres.11266 · Cited by 8
Su, W., Niu, X., Ji, H., Xu, Y. X. Z., Zhong, L., Wang, S., Tang, D., Zhou, X., Zhang, Q., & Zhou, J. (2020) · Journal of Cancer · doi:10.7150/jca.39083 · Cited by 6
“The cut-off values for the proteins were shown as reported previously [7, 26-32]: CD10 (30%), BCL6 (30%), MUM1 (30%), PI3K (30%), AKT2 (20%), JAK2 (30%), STAT3 (30%), MAPK (20%), BCL10 (20%), NF-κB p50 (nuclear 20%), Myc (40%), BCL2 (50%), MCL1 (50%), BCL-xL (50%), Ki67 (70%) and P53 (30%) respectively.”
Long Non-Coding RNA CD27-AS1-208 Facilitates Melanoma Progression by Activating STAT3 Pathway
Ma, J., Shi, Q., Guo, S., Xu, P., Yi, X., Yang, Y., Zhang, W., Liu, Y., Liu, L., Yue, Q., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2021.818178 · Cited by 6
“The phosphorylation of STAT3 at Tyr705 is positively associated with melanoma development and is a negative prognostic factor for overall survival of melanoma patients (12, 18).”
BackgroundHuismans, A. M., Kroon, H. M., Kam, P. C. A., & Thompson, J. F. (2016) · Springer eBooks · doi:10.1007/978-3-319-28773-7_26 · Cited by 6
Self-citationJiang, X., Li, J., Zhu, P., Zeng, K., Liu, B., Zhang, J., Yung, K., & Deng, B. (2025) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2025.120086 · Cited by 5
Zou, Z., Yin, Y., Lin, J., Hsu, L.-C. J., Brandon, V. L., Yang, F., Jove, R., Jandial, R., Li, G., & Chen, M. Y. (2015) · Journal of neurosurgery · doi:10.3171/2015.3.jns132040 · Cited by 6
Dalvi, S., Jabbour, T. E., Kim, S., Sheehan, C., & Ross, J. (2018) · Indian Journal of Pathology and Microbiology · doi:10.4103/ijpm.ijpm_731_16 · Cited by 4
“Mcl-1 overexpression has been reported in a variety of solid tumors including cholangiocarcinoma,[2] hepatocellular carcinoma,[7] nonsmall cell lung carcinoma (NSCLC),[8] Merkel cell carcinoma,[9] and melanoma[10] but has not been widely studied as a prognostic factor or therapy target in these solid tumors.”
BackgroundCell cycle regulatory markers in melanoma: New strategies in diagnosis and treatment
Afrang, N., & Honardoost, M. (2019) · Medical Journal of the Islamic Republic of Iran · doi:10.47176/mjiri.33.96 · Cited by 4
Nikitakis, N. G., Gkouveris, I., Papadopoulou, E., Daskalopoulos, A., & Sklavounou, A. (2017) · Oral Surgery Oral Medicine Oral Pathology and Oral Radiology · doi:10.1016/j.oooo.2017.10.007 · Cited by 4
Time-Dependent Molecular Changes Following MDMA-Induced Nephrotoxicity
Roghani, M., Golchoobian, R., Mohammadian, M., Shanehbandpour-Tabari, F., Salehi, Z., & Gilaki-Bisheh, S. (2024) · Iranian journal of pharmaceutical research · doi:10.5812/ijpr-145483 · Cited by 2
“These findings align with evidence suggesting that while Bcl-xl and Bcl-2 proteins both serve anti-apoptotic functions, their protein expression is regulated by independent mechanisms, leading to dissociation between their expression changes (49-51).”
ResultRegulation of Apoptosis in Melanoma Cells: Critical Targets for Therapeutic Strategies
Eberle, J., & Fecker, L. F. (2017) · Springer eBooks · doi:10.1007/978-3-319-41319-8_10 · Cited by 2
Adaptation to ER Stress as a Mechanism of Resistance of Melanoma to Treatment
Dong, X., Hersey, P., Hong, K., Tseng, H., Chen, C., & Dong, L. (2011) · InTech eBooks · doi:10.5772/19115 · Cited by 2
Self-citationOvercoming Resistance to BRAF and MEK Inhibitors by Simultaneous Suppression of CDK4
Dong, J. (2013) · InTech eBooks · doi:10.5772/53620 · Cited by 4
“BCL2L1 and BIRC5 are highly expressed in melanoma cells, and increased expression correlates with tumor progression [74, 75].”
BackgroundŠamija, I., Lukač, J., & Kusić, Z. (2010) · Acta Medica Academica · Cited by 3
A Study of C-MYC, SOX10 and BCL-2 Proteins Expression in Head and Neck Mucosal Melanomas
Hsieh, R., Prasad, M. L., Nico, M. M. S., Tavares, H., ALTEMANI, A. M. D. A. M., Macarenco, R., & Lourenço, S. V. (2016) · Journal of cancer research updates · doi:10.6000/1929-2279.2016.05.04.1 · Cited by 2
“They observed that reduction in the BCL2 expression was evident in thick melanoma and in tumor with high dermal mitotic rates, suggesting that it was related to events associated with disease progression [35].”
BackgroundExpression of Bcl-2, Melan A and HMB-45 in Dysplastic Nevi.
Pătraşcu, O. M., Costache, M., Dumitru, A. V., Mehotin, N. C., Sajin, M., & Lăzăroiu, A. M. (2016) · Europe PMC (PubMed Central) · Cited by 3
Murphy, K. A. (2008) · Rutgers University Community Repository (Rutgers University) · doi:10.7282/t3wh2qb8 · Cited by 2
“It’s also known that reduced expression of MITF occurs during melanoma progression (Zhuang et al., 2007) suggesting that MITF may play a role in melanoma progression through the control of ECM degradation.”
BackgroundMolecular pathology of microRNA-339 during tumor progression
Akhlaghipour, I., Taghehchian, N., & Moghbeli, M. (2025) · Cell Division · doi:10.1186/s13008-025-00170-0 · Cited by 1
“MCL1 up regulation is found to be contributed with melanoma chemo resistance following direct therapeutic targeting of MEK and BRAF [79, 80].”
Hersey, P., Gallagher, S. J., & Mijatov, B. (2013) · Resistance to targeted anti-cancer therapeutics · doi:10.1007/978-1-4614-7654-2_7 · Cited by 1
Self-citation(2017) · Cancer Studies and Therapeutics · doi:10.31038/cst.2017215
(2017) · Cancer Studies and Therapeutics · doi:10.31038/cst.2017105 · Cited by 1
“However, such a combination may not be applied to all cancers, because overexpression of Bcl-2 is associated with a good prognosis in some other malignancies [42].”
BackgroundTissue-Based Protein Biomarkers in Melanoma: Immunohistochemistry: (A) Diagnosis
Ohsie, S. J., Horst, B. A. J., Cochran, A. J., & Binder, S. W. (2011) · Springer eBooks · doi:10.1007/978-1-60761-433-3_12 · Cited by 1
Hachenberg, T., Meyer, J., Sielenkämper, A. W., Kraft, W., Vogt, B., Breithardt, G., & Lawin, P. (1993) · PubMed · Cited by 2
The Role of Cellular Differentiation and Cell Fate in Malignant Melanoma
Kuzel, P., & Andy, J. C. (2011) · InTech eBooks · doi:10.5772/20002
“melanocytes, AP-2 is responsible for the regulation of a host of normal cellular functions, including DNA repair, cell cycle arrest and cell adhesion (Zhuang et al., 2007).”
Biomarkers for Melanoma Diagnosis and the Technologies Used to Identify Them
Mori, T., & Kang, J. (2011) · InTech eBooks · doi:10.5772/22454 · Cited by 1
“3) Other studies suggested a decrease in the expression of antiapoptotic Bcl-2 in metastatic melanoma (Fecker et al., 2006; Zhuang et al., 2007).”
Assessment of prognostic markers in benign and malignant melanocytic tumours
Svjatoha, V. (2011) · Figshare
Sub-Nuclear Localization and Tumorigenic Function of the Oncoprotein Dek.
Khodadoust, M. S. (2010) · Deep Blue (University of Michigan)
MITF (microphthalmia-associated transcription factor)
Riddle, N., & Zhang, P. (2013) · Atlas of Genetics and Cytogenetics in Oncology and Haematology · doi:10.4267/2042/51811
Role of tumour suppressor ING3 in melanoma pathogenesis
Wang, Y. (2009) · cIRcle (University of British Columbia) · doi:10.14288/1.0066899
“Recent studies demonstrate that both Mcl-1 and Bcl-XL are overexpressed in melanoma and correlates with melanoma tumor progression (Zhuang et al., 2007), implying that these two anti-apoptotic factors may be key players in overriding the apoptotic signals generated by increased Bax and decreased Bcl-2 expression.”
Background[Transcription factors in the development and progression of melanoma].
Lesiak, K., Sztiller-Sikorska, M., & Czyż, M. (2007) · PubMed · Cited by 5
STAT3 and Src Signaling in Melanoma
Kujawski, M., Cherryholmes, G. A., Priceman, S. J., & Yu, H. (2011) · Springer eBooks · doi:10.1007/978-1-61779-407-0_7
Dissecting early mechanism of melanoma cell resistance to cytotoxic T lymphocyte attack
Khazen, R. (2016) · theses.fr (ABES) · doi:10.70675/9a24d3a2z9142z4af9z8e45zd0ed9fba6cfb
Anti-GD3 antibodies are targeting molecules for delivery of siRNA to melanoma
Wu, M. W.-Y. (2010) · QSpace (Queen's University Library)
The role of inhibitor of apoptosis (IAP) family member survivin in prostatic disease
McIlwain, D. W. (2017) · IUScholarWorks (Indiana University) · doi:10.7912/c2/328
Keuling, A. M. (2010) · ERA: Education and Research Archive (University of Alberta) · doi:10.7939/r3cq5d
Characterisation and regulation of the Egfr-Egfr ligand system in fish models for melanoma
Laisney, J. A. G. C. (2010) · Online Publication Service of Würzburg University (Würzburg University)
Modification of Bcl-x and Mcl-1 pre-mRNA splicing using splice-switching oligonucleotides
Bauman, J. A. (2011) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/rjnh-m743
Dong, J., & Chet, L. (2011) · InTech eBooks · doi:10.5772/18692
“BCL2L1 and BIRC5 are highly expressed in melanoma cells, and increased expression correlates with tumor progression (Piras et al., 2007; Zhuang et al., 2007).”
BackgroundJiang, C. C., Lucas, K. M., Avery‐Kiejda, K. A., Wade, M., de Bock, C. E., Thorne, R. F., Allen, J. C., Hersey, P., & Zhang, X. D. (2023) · doi:10.1158/0008-5472.c.6496538
Self-citationArmstrong, J. L., Corazzari, M., Martin, S., Pagliarini, V., Falasca, L., Hill, D. S., Ellis, N., Sabah, S. A., Redfern, C. P. F., Fimia, G. M., et al. (2023) · doi:10.1158/1078-0432.c.6519183.v1
Antimetastatic activity of seongsanamide B in γ-irradiated human lung cancer
Ryoo, G.-H., Kim, G. J., Han, A., Jin, C. H., Lee, H., Nam, J., Choi, H., & Jung, C. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e20179 · Cited by 1
Unveiling the role of RAI14 in cancer: Biological significance and translational perspectives
Chong, Z. X. (2025) · Seminars in Oncology · doi:10.1016/j.seminoncol.2025.152412
Oncogene functions in human cancer
Tang, J. (2010) · ResearchSpace (University of Auckland)
Regulation of Apoptosis in Melanoma Cells: Targets for Therapeutic Strategies
Eberle, J., & Fecker, L. F. (2011) · Springer eBooks · doi:10.1007/978-3-7091-0371-5_10
“This may be related to the finding that expression of Bcl-2 may even be reduced in metastatic melanoma ( Zhuang et al. 2007 ).”
BackgroundLinlin, B., Lihua, Z., Guo, L., Sai, W., & Li, A. (2026) · Iranian Journal of Science · doi:10.1007/s40995-026-02011-3
“These ATP-binding cassette transporters are known to promote drug efflux and reduce intracellular drug accumulation, thereby contributing to chemotherapy failure (Bromberg et al. 1999; Aoki et al. 2003 ; Zhuang et al. 2007).”
Lv, Q., Liang, E., Bai, L., Huang, S., Song, J., Yin, H., & Li, Y. (2026) · Frontiers in Veterinary Science · doi:10.3389/fvets.2026.1826884
“Clinical data from human patients demonstrate a negative correlation between STAT3 and MITF expression (21), yet our rodent studies reveal a more nuanced relationship where both pathways can co-exist in a context-dependent manner.”
Shan, C., Guo, M., Feng, F., Wang, X., Mohang, L., Xu, W., Jia, K., Liu, Y., & Jia, Y. (2026) · The EPMA Journal · doi:10.1007/s13167-026-00465-4
“Continuous IL-6 stimulation activates the JAK2/STAT3 pathway, upreg - ulating BCL-xL, MCL-1, and Cyclin D1, which inhibits epithelial apoptosis [232, 233].”
Targeting Apoptotic Pathways in Melanoma
Hersey, P., & Zhang, X. D. (2011) · Springer eBooks · doi:10.1007/978-1-61779-407-0_9
Self-citation
Metadata
- Authors
- Zhuang, L., Lee, C. S., Scolyer, R. A., McCarthy, S. W., Zhang, X. D., Thompson, J. F., & Hersey, P.
- Affiliations
- The University of Sydney (AU)
- Royal Prince Alfred Hospital (AU)
- Corresponding author
- Hersey, Peter
- Venue
- Modern Pathology
- Publisher
- Elsevier BV
- Published
- 2007-04
- Volume
- 20
- Issue
- 4
- Pages
- 416-426
- ISSN
- 0893-3952 (ISSN-L)
- OpenAlex
- W2086851270
- Cited by
- 202
- References
- 58
- Citations by year
- 2026: 4 · 2025: 4 · 2024: 4 · 2023: 5 · 2022: 3 · 2021: 6 · 2020: 7 · 2019: 9 · 2018: 7 · 2017: 13 · 2016: 17 · 2015: 10 · 2014: 11 · 2013: 17 · 2012: 8
- FWCI
- 8.91
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 5764 d)
- Locations
- Modern Pathology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Cancer Research Institute
- Medical Research Council
- National Health and Medical Research Council
- National Medical Research Council
- Topics
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- melanoma progression, Bcl-2, Bcl-xL, Mcl-1, anti-apoptotic proteins, apoptosis, STAT3 phosphorylation, MITF, AP2 transcription factor, tumor thickness, metastasis, benign nevi
- MeSH terms
- Adolescent, Adult, Aged, Aged, 80 and over, Female, Humans, Lymph Nodes, Lymphatic Metastasis, Male, Melanoma, Middle Aged, Neoplasm Proteins, Skin Neoplasms, Biomarkers, Tumor, Disease Progression, Fluorescent Antibody Technique, Indirect, Proto-Oncogene Proteins c-bcl-2, Transcription Factor AP-2, STAT3 Transcription Factor, bcl-X Protein, Microphthalmia-Associated Transcription Factor, Myeloid Cell Leukemia Sequence 1 Protein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.